Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - The Lancet, 2010 - thelancet.com
Background Present interferon-based standard of care treatment for chronic hepatitis C virus
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a …
S Pol, RH Ghalib, VK Rustgi, C Martorell… - The Lancet infectious …, 2012 - thelancet.com
Background Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are
available, but they are limited by tolerability and dosing schedules. Once-daily daclatasvir, a …
available, but they are limited by tolerability and dosing schedules. Once-daily daclatasvir, a …
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus …
C Hézode, T Asselah, KR Reddy, T Hassanein… - The Lancet, 2015 - thelancet.com
Summary Background Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global
HCV infections. Because interferon-containing treatments for genotype 4 infection have low …
HCV infections. Because interferon-containing treatments for genotype 4 infection have low …
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Y Suzuki, K Ikeda, F Suzuki, J Toyota, Y Karino… - Journal of …, 2013 - Elsevier
Background & Aims Improved therapeutic options for chronic hepatitis C virus (HCV)
infection are needed for patients who are poor candidates for treatment with current …
infection are needed for patients who are poor candidates for treatment with current …
Preliminary study of two antiviral agents for hepatitis C genotype 1
AS Lok, DF Gardiner, E Lawitz… - … England Journal of …, 2012 - Mass Medical Soc
Background Patients with chronic hepatitis C virus (HCV) infection who have not had a
response to therapy with peginterferon and ribavirin may benefit from the addition of multiple …
response to therapy with peginterferon and ribavirin may benefit from the addition of multiple …
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Background An unmet need exists for interferon-free and ribavirin-free treatments for chronic
hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir …
hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir …
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
C Hézode, GM Hirschfield, W Ghesquiere, W Sievert… - Gut, 2015 - gut.bmj.com
Objective To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with
pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. Design In this Phase …
pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. Design In this Phase …
[PDF][PDF] Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
H Kumada, Y Suzuki, K Ikeda, J Toyota, Y Karino… - …, 2014 - Wiley Online Library
All‐oral combinations of direct‐acting antivirals may improve efficacy and safety outcomes
for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates …
for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates …
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE …
Summary Background In Egypt, chronic hepatitis C virus (HCV) infection occurs in around
10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis …
10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis …
Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C
JA Gutierrez, EJ Lawitz, F Poordad - Journal of viral hepatitis, 2015 - Wiley Online Library
The treatment environment for chronic hepatitis C has undergone a revolution, particularly in
genotype 1. Gone are interferon‐based therapy and its associated tolerability challenges …
genotype 1. Gone are interferon‐based therapy and its associated tolerability challenges …